Forest Laboratories and Nabriva Therapeutics have collaborated to develop a novel antibacterial agent, BC-3781.
According to the agreement, Nabriva will receive $25m fund to conduct certain development activities related to BC-3781 over the next 12 months.
Forest has the exclusive right to acquire Nabriva, depending upon certain contingencies, during the 12-month period.
Further financial or other terms related to the transaction, which is subject to customary regulatory clearances including termination of the applicable Hart-Scott-Rodino waiting period, were kept confidential.
BC-3781, which belongs to a novel class of antibiotics, the pleuromutilins, exhibits microbiological activity against a range of gram-positive pathogens as well as certain gram-negative organisms, often implicated in respiratory infections.